Clinical Guides
Medication-Overuse Headache
A clinically focused, India-facing guide to recognising medication-overuse headache, withdrawing acute medicines safely, treating the underlying headache disorder and avoiding recurrence.
MedNext Academy | 14 min read
Medication-Overuse Headache
A clinically focused, India-facing guide to recognising medication-overuse headache, withdrawing acute medicines safely, treating the underlying headache disorder and avoiding recurrence.
Summary
Medication-overuse headache, often called MOH, is a secondary headache disorder occurring in a person with a pre-existing headache disorder who has headache on 15 or more days per month and regularly overuses medicines taken for acute or symptomatic headache treatment for more than three months. The threshold is medication-specific: triptans, ergot derivatives, opioids and combination analgesics are generally overused on 10 or more days per month, while non-opioid analgesics such as paracetamol, aspirin or non-steroidal anti-inflammatory drugs are generally overused on 15 or more days per month. A person may overuse several classes even if no single class reaches its own threshold.
MOH is an interaction between a susceptible patient and frequent acute medication, not a moral failure or proof of addiction. Migraine and tension-type headache are common underlying disorders; both diagnoses should be recorded when criteria are met. Headache often becomes frequent, less distinct and less responsive to treatments, but phenotype alone cannot confirm MOH. A diary of headache days and every acute medicine, including combination tablets, caffeine-containing products and medicines bought without prescription, is essential.
The core treatment is supported withdrawal of the overused acute medication alongside a plan for the underlying primary headache. Current guidelines advises stopping all overused acute medicines for at least one month, usually abruptly, warning that headache can initially worsen, providing follow-up and considering prevention for the primary disorder. Strong opioids, major comorbidity, failed withdrawal or diagnostic uncertainty require specialist assessment. This guide is educational, not a personal detoxification protocol.
How Common Is It?
MOH is common enough to matter in primary care and neurology but its frequency varies by country, case definition, pharmacy access, healthcare system and whether surveys verify medication use with a diary. ICHD-3 notes epidemiological evidence from many countries that more than half of people with headache on 15 or more days per month have medication overuse headache. That statement does not mean that more than half of all people with headache have MOH, nor does it supply an India-wide prevalence estimate.
Population estimates are especially uncertain where medicines are purchased over the counter, shared in households, supplied by multiple clinicians or recorded under brand names. India has diverse state services and retail markets; no single national register reliably measures MOH prevalence, withdrawal success or opioid-related risk. A hospital headache-clinic figure cannot represent community prevalence because referral selects frequent, refractory or financially able patients. Conversely, sales data cannot diagnose MOH because analgesics may be used for fever, injury or menstrual pain.
The practical burden includes missed work, repeated consultations, drug adverse effects and delayed preventive care for migraine or tension-type headache. Counting acute-medication days is more useful than counting tablets alone: two doses taken on one day usually count as one medication-use day for classification. Care teams should record calendar month, headache days, medication class, source, dose, indication and concurrent caffeine, alcohol, sleep or mood factors. These measurements make follow-up honest and allow services to report uncertainty rather than converting a screening threshold into a prevalence claim.
Risk Factors
The necessary context is a pre-existing headache disorder plus frequent use of acute or symptomatic medication. Migraine is a common underlying disorder, and frequent migraine attacks create understandable pressure to take fast relief repeatedly. Risk rises when the person has inadequate access to a preventive plan, receives repeat prescriptions without review, uses more than one prescriber or pharmacy, or buys combination analgesics without recognising their ingredients. Opioids and combination analgesics require particular caution because they can bring dependence, sedation, constipation, respiratory risk and withdrawal problems in addition to headache worsening.
Do not infer MOH from a medicine list alone. A person might take regular analgesia for arthritis or postoperative pain and have frequent headache from another cause; ICHD-3 still requires the headache context and exclusion of a better diagnosis. Risk assessment therefore asks what each medicine is for, how many days it is taken, whether it contains caffeine or codeine, whether a triptan is paired with an analgesic, and whether medicines are being used in an attempt to prevent rather than treat attacks. Diaries are more accurate than retrospective monthly estimates.
Depression, anxiety, sleep disturbance, socioeconomic stress and fear of the next headache can complicate withdrawal but should not be used to dismiss pain as psychological. Pregnancy, renal or hepatic disease, peptic-ulcer risk, cardiovascular disease, substance-use disorder and polypharmacy alter both acute medicine hazards and the withdrawal plan. A change in headache pattern, neurological signs, fever, cancer history or immunosuppression may signal secondary headache rather than MOH and must be assessed before a simplistic instruction to stop all medicines.
Diagnosis
History
Document the primary headache diagnosis, onset of frequent headache, number of headache days each month, each acute medicine and the days it is taken for at least three months. Ask specifically about generic and brand-name paracetamol, NSAIDs, aspirin, triptans, ergot medicines, opioids, butalbital where available, caffeine-containing combinations, antiemetics and supplements. Establish whether medicines are used for headache or another pain condition, who supplied them, current dose, past withdrawal, dependence symptoms and adverse effects. A calendar or electronic diary is usually more reliable than memory.
Examination
Perform blood pressure, general and complete neurological examination, including fundus where indicated. Examine for medication toxicity and alternative pain generators: gastrointestinal bleeding symptoms, renal-risk features, opioid sedation, neck or jaw pathology, infection and ocular signs. Screen sensitively for depression, anxiety, sleep disorder, alcohol or substance use and self-harm risk. A normal examination supports neither MOH nor its exclusion; it simply reduces concern for some secondary disorders when the history also fits.
Investigations
ICHD-3 requires headache on at least 15 days per month in a person with pre-existing headache, regular medication overuse for more than three months and no better diagnosis. There is no laboratory test for MOH. Obtain tests only for specific concerns, such as full blood count and renal function for suspected analgesic toxicity, pregnancy testing where treatment choices require it, or neuroimaging when red flags or atypical presentation indicate. Record the underlying primary headache and MOH together when both criteria are fulfilled. Classify the overused class or classes; when the account is unclear, diary follow-up is safer than false precision.
Differential Diagnosis
Chronic migraine is commonly present with MOH and is not an either-or diagnosis. ICHD-3 specifically directs clinicians to code both when criteria for both are met. Chronic tension-type headache, new daily persistent headache and a chronic cluster headache can also coexist with regular acute-medicine use, but the underlying phenotype, timing and response require re-evaluation after withdrawal. Not every person whose headache improves after stopping medication had proven MOH, and not every person with true MOH improves immediately.
Secondary chronic daily headache must be actively considered. Red flags include thunderclap onset, focal neurological deficit, papilloedema, fever or meningism, new headache with cancer or immunosuppression, pregnancy/postpartum complications, trauma, anticoagulation, age-related vascular symptoms, or a clear progressive change. Raised intracranial pressure, cerebral venous thrombosis, mass lesion, sleep apnoea, medication adverse effects unrelated to MOH and systemic illness may produce frequent headache. Imaging is guided by findings rather than by the fact of analgesic use.
Caffeine withdrawal, opioid withdrawal and medication side effects can cause headache but are coded differently unless the full MOH context exists. Chronic sinus symptoms, dental pain, temporomandibular disorder, cervical pain and eye disease may be relevant contributors, yet should be diagnosed from supportive local findings rather than blamed for any forehead pain. In India, unlabelled or multi-ingredient products can obscure exposure; pharmacists and the patient should identify active ingredients before classifying use. The clinical aim is not to find a convenient label but to avoid missed disease while reducing harmful repeated rescue medication.
Management
Explain the diagnosis in neutral language and agree a written withdrawal plan. Current guidelines recommends stopping all overused acute headache medicines for at least one month, generally abruptly rather than gradually. Explain before starting that headache can worsen temporarily and nausea, poor sleep, anxiety or other withdrawal symptoms may occur. Provide accessible follow-up, a headache-and-medicine diary, sick-leave or family support where needed and a clear route for urgent review. Avoid replacing the overused drug with another frequent rescue medicine, because that can perpetuate the same cycle.
Treat the underlying primary headache in parallel. Current guidelines advises considering preventive treatment for the underlying disorder in addition to withdrawal. The preventive choice depends on whether the phenotype is migraine, tension-type headache or another disorder, as well as pregnancy, comorbidity, prior treatment, kidney and liver function, blood pressure, weight, mood and local availability. Preventive prescribing is not one-size-fits-all and should use current Indian labelling and a clinician-led plan. Non-drug support includes regular sleep, meals, hydration, graded activity, trigger review and behavioural or psychological support when useful; these complement rather than replace diagnosis and medication review.
current guidelines does not recommend routine inpatient withdrawal. Specialist referral or inpatient care may be appropriate for strong opioid use, important comorbidity or repeated failed withdrawal. Review diagnosis and management 4 to 8 weeks after withdrawal starts. Measure headache days, acute-medication days, disability, adverse events and adherence, not merely whether the patient says they feel better. A relapse-prevention plan sets a safe maximum use frequency, names the person who will review prescriptions and makes it easy to seek help before daily rescue medicine resumes.
Prescribing Information
Do not issue repeat acute headache prescriptions without recording the number of medication-use days per month and the active ingredients in every product. The ICHD-3 thresholds are classification thresholds, not permission to prescribe up to the limit. Where a person is nearing frequent use, reassess diagnosis and preventive treatment early. Combination analgesics can conceal opioid, caffeine or multiple analgesic exposure; duplicate paracetamol can produce severe liver injury and duplicate NSAIDs increase gastrointestinal, renal and cardiovascular harm. Pharmacy reconciliation should include non-prescription, herbal and traditional products where ingredients are known.
Abrupt withdrawal is current guidelines' general approach for overused acute headache medicines, but opioid withdrawal and benzodiazepine or other dependence pathways may require individual specialist management. Never advise a patient who uses strong opioids to stop them suddenly from a general web page. Assess withdrawal risk, prescribed indication, dependence, overdose risk, concurrent sedatives, alcohol use, pregnancy and social support. Naloxone access and addiction-medicine referral follow local clinical and legal pathways, not MOH classification alone.
Preventive medicines for migraine or other primary headaches have distinct contraindications, monitoring and pregnancy considerations. Selection should be individualised by the prescriber and current Indian product information; this guide deliberately avoids a universal dose schedule. Use one prescriber or a coordinated record whenever possible, give the patient a written list of medicines that count as acute treatment, and document the plan for an unavoidable separate painful condition. Pharmacists should be invited to flag early refills, duplicate ingredients and requests for codeine-containing combinations. The objective is rational prescribing, not withholding humane pain care.
When to Refer
Refer to neurology, a headache clinic or a clinician with headache expertise when diagnosis is uncertain, red flags are present, the patient has chronic daily headache with an atypical pattern, or withdrawal has failed despite a documented supported attempt. Urgent evaluation is needed for thunderclap headache, new focal deficit, papilloedema, altered consciousness, fever or meningism, painful red eye with visual loss, pregnancy/postpartum warning signs, cancer, immunosuppression or suspected raised intracranial pressure. These are not explained away by frequent analgesic use.
Seek specialist and possibly inpatient advice for strong opioid use, complex sedative co-use, suspected substance-use disorder, severe psychiatric illness, serious medical comorbidity, pregnancy, inability to maintain hydration or nutrition, repeated emergency attendance or unsafe home circumstances. Addiction medicine, psychiatry, pain medicine, obstetrics, nephrology or gastroenterology may need to work with the headache clinician; referral should be coordinated rather than passed from service to service. A person with suicidal thoughts, intent or inability to stay safe needs emergency mental-health assessment alongside pain treatment.
In India, access to specialist headache care and supervised withdrawal differs sharply between settings. A referral plan should identify a reachable government or private facility, interim clinician, emergency department and language support, and should account for travel, medicine cost and work duties. Do not promise hospital admission, a branded preventive medicine or a detox bed that is not locally available. Community pharmacists can assist with reconciliation and refill monitoring, but should not be asked to diagnose a dangerous secondary headache.
Red Flags
Immediate assessment is warranted for a sudden maximal headache, headache after trauma, fever with neck stiffness, altered mental status, seizure, focal weakness or sensory loss, new persistent visual change, papilloedema, severe hypertension with end-organ symptoms, or rapidly progressive pattern. A headache diagnosis made years ago does not protect against new pathology. In particular, medication overuse must never delay evaluation for cerebral venous thrombosis, intracranial haemorrhage, meningitis, giant-cell arteritis, glaucoma, mass lesion or carotid dissection when the presentation points there.
Medication-related danger also matters. Seek urgent help for black stools, vomiting blood, severe abdominal pain, jaundice, markedly reduced urine, confusion, extreme drowsiness, slow or shallow breathing, overdose concern, allergic reaction, severe chest pain or syncope. These may reflect toxicity from NSAIDs, paracetamol, opioids, triptans or an unrelated emergency. People taking opioids with alcohol, benzodiazepines or other sedatives have increased respiratory risk; their care requires a specific addiction and safety plan, not a blanket abrupt-withdrawal message.
Withdrawal can temporarily worsen headache, but dehydration, persistent vomiting, inability to take essential regular medicines, severe agitation, psychosis, self-harm thoughts or failure to care for dependants needs urgent review. Red flags in a child, adolescent, older adult, pregnant person or person with renal, liver or cardiovascular disease should lower the threshold for clinician assessment. The safety-net must be written in language the patient and family understand, with an emergency number and a statement that they can return if the diagnosis no longer feels right.
Indian Clinical Context
ICHD-3 is an international classification and international guidelines is a United Kingdom guideline. They are valuable clinical anchors but do not automatically determine Indian drug schedules, over-the-counter status, pharmacy practice, product composition, public-hospital formularies or access to addiction services. Verify the current Indian label and active ingredients of each product, especially fixed-dose combinations and codeine-containing preparations, with a pharmacist or official prescribing source. Avoid asserting a national prevalence or a universal withdrawal pathway when reliable India-wide evidence and services vary.
Patients may obtain analgesics from several outlets, use brand names unfamiliar to the clinician, share medicines within family or combine prescriptions with traditional products. A non-judgemental medicine reconciliation is therefore a safety intervention. Ask the patient to bring strips, bottles and photographs of labels. Document medicine-use days instead of only tablet numbers. Explain the difference between stopping overused headache rescue medicine and neglecting treatment for hypertension, epilepsy, diabetes, cancer pain or another established condition; those drugs need coordination with their own prescribers.
Cost and geography affect feasibility. A person may rely on a low-cost combination tablet because preventive review, paid leave, transport or neurology access is unavailable. Offer a realistic follow-up point in primary care, public hospital or telehealth where clinically suitable, and work with a pharmacist on refill alerts. NMC-oriented training supports rational prescribing, communication, adverse-effect recognition, emergency triage and referral, but institutions should map the exact current competency locally. This quarantined draft is has been reviewed by the MedNext Clinical Team and does not claim completed Indian guideline endorsement.
NMC Competency Mapping
Medication-overuse headache supports competency-based learning in clinical history, rational pharmacotherapy, patient communication, patient safety and referral. Rather than inventing a single NMC code, learners should map it to their currently adopted medicine, pharmacology, psychiatry and emergency-care outcomes. They should identify all acute products by generic ingredient, calculate medication-use days, recognise duplicate paracetamol or NSAID exposure, distinguish an indication for ongoing opioid therapy from headache overuse, and document the underlying primary headache alongside MOH where appropriate.
At Know and Know How level, learners explain the ICHD-3 diagnostic framework and medication-class thresholds, common short-term withdrawal effects and the purpose of prevention. At Show How level, they take a non-stigmatising history, create a calendar diary, screen for red flags and substance-related risk, counsel a patient about anticipated worsening, and communicate a follow-up plan in the patient's preferred language. Prescribing decisions, opioid changes and preventive selection should be supervised and based on the local formulary and patient-specific contraindications.
A useful assessment vignette gives a patient with migraine, 22 headache days and frequent combination tablets, then asks for classification, alternative diagnoses, safety checks, withdrawal counselling and a 4-to-8-week review. A second vignette should include black stools, pregnancy or focal neurological signs, testing that learners do not anchor on MOH. Professional practice includes respecting pain, avoiding blame, coordinating with pharmacists and other prescribers, documenting uncertainty and escalating self-harm risk. Consult the current NMC regulations and institutional curriculum for formal code-level mapping.
Key Exam Pearls for NEET PG
ICHD-3 medication-overuse headache requires: pre-existing headache disorder, headache on 15 or more days per month, regular overuse of acute or symptomatic headache medicine for more than three months, and no better diagnosis. Record the underlying headache as well as MOH; chronic migraine and MOH can coexist. Triptans, ergot derivatives, opioids and combination analgesics have a 10-or-more-days-per-month threshold. Non-opioid analgesics such as paracetamol, aspirin and NSAIDs have a 15-or-more-days-per-month threshold. Multiple classes can collectively cause overuse.
The fundamental management answer is education plus withdrawal of overused acute medicines. Current guidelines advises stopping all overused acute medicines for at least one month and generally abruptly, warning of short-term worsening and withdrawal symptoms, providing follow-up and considering preventive treatment for the underlying primary headache. Do not routinely offer inpatient withdrawal. Consider specialist referral or inpatient withdrawal for strong opioid use, relevant comorbidity or repeated unsuccessful attempts; review after 4 to 8 weeks.
Exam traps are to call every daily headache MOH, to forget secondary-headache red flags, or to advise unsupervised abrupt opioid cessation. There is no confirmatory laboratory test. A headache diary and medicine reconciliation establish exposure. Medication days matter more than tablet count. Combination products may contain multiple active ingredients and create duplicate paracetamol, NSAID, caffeine or opioid exposure. In real practice, a safe withdrawal plan includes the diagnosis, treatment of the underlying headache, adverse-effect checks, mental-health assessment and a route back to care.
Frequently Asked Questions
Can medication-overuse headache happen with medicines bought without a prescription?
Yes. Classification depends on the active ingredient and the number of medication-use days, not whether a clinician prescribed it. Paracetamol, NSAIDs, aspirin, triptans, opioids and combination tablets can all be relevant. Bring packets, strips or photos of labels to review because brand names can hide duplicate ingredients. Do not abruptly stop medicines prescribed for another serious condition without coordinating with that prescriber.
Will headache always disappear immediately when the medicine is stopped?
No. Headache often worsens temporarily during withdrawal, and improvement is not guaranteed or immediate. Current guidelines advises explaining this in advance and reviewing care 4 to 8 weeks after withdrawal begins. The underlying migraine, tension-type headache or another disorder may still need preventive treatment and reassessment. Worsening with neurological red flags, persistent vomiting, dehydration or inability to stay safe needs urgent clinical review.
Should everyone stop opioid pain medicines abruptly for suspected MOH?
No. current guidelines' general MOH advice is abrupt withdrawal of overused acute headache medicines, but strong opioid use, dependence risk, co-use of sedatives, serious comorbidity, pregnancy or failed attempts need specialist assessment and sometimes supervised withdrawal. Unsupervised opioid cessation can be unsafe. The treating team must balance headache management, the original pain indication, overdose prevention and a support plan.
How can MOH be prevented after successful withdrawal?
Track headache days and every acute-treatment day, use a written limit agreed with the clinician, and seek review before repeat rescue medicine becomes frequent. Ensure the underlying headache diagnosis and preventive plan are addressed. Use one coordinated prescriber or medication list where possible, ask pharmacists to flag early repeats and avoid concealed duplicate ingredients in combination products. Prevention is practical support, not blame.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic